Visum Technologies seeking admission to The AQSE Growth Market. The Company’s business is to own and operate an “on-ride” video and photographic camera system that it sells and/or licenses to customers (being theme parks, ride manufacturers, souvenir imaging providers, and other leisure operators). Due 30 June.
Disko Exploration. Bluejay Mining (JAY.L) is undertaking a review into a demerger and potential separate stock market listing, on a London based stock exchange of its wholly owned subsidiary Disko Exploration Limited. Disko currently holds the following interests: 1. Disko-Nuussuaq nickel-copper-cobalt-PGE project in Greenland which entered into a definitive joint venture agreement with KoBold Metals Company to execute an extensive exploration program in 2022 for battery metals (49% owned by Disko). 2. Kangerluarsuk, a 100% owned lead-zinc-silver project in Greenland. 3. Thunderstone, a 100% owned gold-base metals & REE project in Greenland. Timing TBC.
Altona Rare Earths, the AQSE listed mining exploration Company focused on the evaluation, acquisition and development of Rare Earth Elements mining projects in Africa, intends to join the Main Market. Admission to trading of the Company’s Ordinary Shares on the AQSE Growth Market will be cancelled simultaneously with Admission. It is also proposed that on Admission, the Company will change its EPIC from AQSE:ANR to REE. The Company also seeks to raise funds to finance its current and future rare earths mining projects in Southern and Eastern Africa. Due June 2022.
Anpario 545p £130.0m (ANP.L)
AGM Statement from the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity. “Group sales for the five months to 31 May 2022 are just ahead of last year which we consider a good performance given China’s recent Covid lockdown and the Russia – Ukraine conflict, both of which have affected our sales performance. As anticipated, we experienced significant raw material price inflation, which has remained at elevated levels, and combined with historically high logistics costs has led to a fall in our gross margins. We have though, as a priority, been successfully passing on this inflation through planned sales price increases and overheads are being closely managed. To mitigate the continued disruption in global supply chains we have increased finished goods inventory in our subsidiaries worldwide and increased raw material stockholding at our production site following the recent expansion and upgrade in storage capacity. It is vital that we maintain continuity of supply to our customers who are experiencing significant cost pressures from the high price of animal feed. Encouragingly, international travel and tourism is increasing and should lead to a corresponding uplift in meat consumption. We are excited by the potential of both existing and new products including pHorce® which is proving its value to pig producers worried about virus-contaminated feed and as a replacement for zinc oxide (ZnO) which is banned in piglet diets from June 2022 in the European Union. Our new omega 3 supplement, Optomega® Algae, has generated a lot of interest due to its sustainable source, from which we expect to convert this interest into growing sales. The Company continues to invest in both product technology and its global sales channels to deliver effective innovative solutions for the animal production industry.”
Arecor Therapeutics 370p £103.0m (AREC.L)
The biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a top five global pharmaceutical company. Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop improved, stable, high concentration liquid formulations of its proprietary products. The Company will fund the initial development work and has the option to acquire the rights to the new proprietary formulations and associated intellectual property under a technology licensing model. Sarah Howell, Chief Executive Officer of Arecor, said: “This collaboration expands our partner portfolio of high-profile pharmaceutical companies. The growing recognition of how the Arestat™ platform can enhance a broad range of therapeutic products is testament to our expertise and innovation in formulation science. For our partners, we are able to significantly improve their products to enable patient friendly treatment regimens that are effective, safe and more convenient, which in turn can lead to better adherence and health outcomes, benefitting healthcare systems as a whole.”
ChallengerX 1.4p £3.9m (AQSE:CXS)
ChallengerX announces the signing of a Digital Asset Monetisation Agreement with Triad Endeavour Sports & Entertainment. The agreement carries an initial term of five years and will immediately see Triad Endeavour onboarded into the CXSports Money Pages platform. Additional Money Pages will also be created for many of the events and talents which are under Triad Endeavour’s management. Triad Endeavour is an event promotion and talent management company working across sports, theatre, film, music, podcasting, and sportswear. Its headline promotion, the Ultimate Fight League (UFL), has seen a roster of esteemed fighters like Charlie Milner and Chris Duncan from leagues such as Bellator and the UFC competing. Triad Endeavour co-founder Sayed Gilani said, “We are a small team punching well above our weight and we’re forever in need of additional capital to take our UFL event to the next level. We see this agreement as an important step forward in generating much-needed revenues and growing our league.”
Genedrive 20.5p £19.0m (GDR.L)
The near patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (NICE) has started an evaluation of the Genedrive® MT-RNR1 test via their Diagnostics Assessment Programme (DAP). DAP evaluations are designed to provide robust recommendations on the use of new products, which is presented in the form of NICE guidance, and to promote rapid and consistent adoption of clinically innovative and cost-effective diagnostic technologies in the NHS. An independent advisory committee considers the evidence provided, makes draft recommendations for public consultation and ultimately makes final recommendations for publication in NICE guidance. The guidance produced is used by NHS commissioners, practitioners, healthcare operational managers and purchasing and procurement organisations. Genedrive’s assay is the world’s first rapid point of care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given certain antibiotics. Those that carry the variant can then be given alternative treatments following detection of the variant by the Genedrive® MT-RNR1 test.
Goldplat 9.9p £16.5m (GDP.L)
The Gold producer, with international gold recovery operations located in South Africa and Ghana, announced the grant of its Water Use License in South Africa. The Department of Water and Sanitation of the Republic of South Africa has authorised the water use by Goldplat Recovery (Pty) Limited (a subsidiary of the Group in South Africa), which includes the abstraction and use of water in its recovery processes and the impact of its disposal of tailings on a new tailings’ storage facility (TSF), according to the conditions set out in the license, which is valid for 12 years. The new TSF, which is adjacent to the current TSF, will be constructed over the next 4 months at a remaining cost of £350k. The new TSF is expected to have sufficient capacity to store the tailings we will produce in our current operations for the next 7 years. The new TSF will also allow us to divert all deposition from the current facility, which will provide us with the ability of processing the current facility to recover the JORC resource of an estimated 81,959 ounces of gold through a third-party facility. To process the current TSF through a third-party facility, it will require approval to install a pipeline to this third-party processing facility and will need to finalise commercial agreements with the third-party. Approval expected by the end of the current calendar year.
Immotion 4p £16.6m (IMMO.L)
The UK-based immersive entertainment group, has entered into a three-year licensing deal for the Chinese Aquarium market. The Company will license a select number of its oceanographic virtual reality experiences under its ‘Undersea Explorer’ brand. The contract will be with Chinese Virtual Reality company, Leke VR, a company that Immotion has dealt with for the past 4 years. Each of the experiences will operate on motion platforms in a multi-seated environment. The experiences will be installed into an initial 15 aquariums on 1 July 2022, with the intention to roll the experiences out to many more aquariums. The initial installations into the 15 aquariums will total 180 seats with an annual footfall in excess of 32m visitors across all sites. Immotion will receive a licence fee of RMB 2.10 (circa £0.25) per play from each location.
IQE 32.2p £259.1m (IQE.L)
The supplier of compound semiconductor wafer products and advanced material solutions to the global semiconductor industry, announced a formal commitment to Net Zero carbon neutrality across its operations by 2050, in accordance with the Science Based Targets initiative. As part of this commitment, IQE will formulate science-based targets to reduce greenhouse gas emissions in line with the SBTi Net Zero Standard, which seeks to limit global warming to 1.5°C. The SBTi defines and promotes best practice in emissions reductions and Net Zero targets in line with climate science. IQE and its Board remain committed to the implementation of Environmental, Social and Governance best practice across the Group. Today’s announcement marks a significant step for IQE’s ESG Committee following its establishment in January 2022, as it continues to build upon IQE’s strategy to deliver sustainable growth. The Board-level group oversees the Group’s ESG activities and performance against commitments, such as those announced today, for the long-term benefit of all stakeholders.
NWF Group 221p £108.6m (NWF.L)
The specialist distributor of fuel, food and feed across the UK, today announces a trading update for the year ended 31 May 2022. The Group has delivered a record year, in line with its trading update issued on 10 May 2022, and a materially stronger performance than had been expected at the beginning of the financial year. Cash generation has remained strong and the Group was cash positive at the year-end, compared to reporting net debt last year. Fuels: Outstanding performance which benefitted from very significant short-term volatility in oil prices and periods when the UK market was supply constrained. The teams in the Group’s 25 depots have focused on maintaining service to existing customers. Food: A strong performance across the year with warehouses at an effective operating capacity, and the achievement of significant efficiency improvements. The business has also been successful at passing on inflationary costs by working closely with customers and maintaining high service levels. Feeds: Good recovery in performance in the second half with the business effectively managing the commodity market price increases and volatility, particularly in the final quarter. Positively, increases in milk prices have been implemented to ensure farmers are incentivised to produce milk despite having higher energy, fertiliser, and feed price inputs.
Thruvision 25.8p £37.8m (THRU.L)
The leading provider of “safe distance” people-screening technology to the international security market announced the appointment of Victoria Balchin as Chief Financial Officer with effect from 1 October 2022. Victoria qualified as a chartered accountant with PwC and has held a number of finance roles with British Sky Broadcasting group plc (2000 to 2005) and SABMiller plc (2005 to 2017) before joining Spectris plc in 2017 as Group Financial Controller. In 2019, she was appointed CFO of Brüel & Kjær Vibro, a Spectris business headquartered in Germany, which was sold by Spectris in March 2021 to a large Japanese listed group.
Tintra 100p £14.8m (TNT.L)
The rapidly innovating Bank Technology business, has filed a UK patent application to protect intellectual property that it has created as part of its rapid research and development program. The Patent is numbered GB2208742.3 and will be viewable on the Intellectual Property Office’s website at https://www.ipo.gov.uk/p-pj in due course. The Company will be seeking international patent protection for the verification and authentication of independent digital wallets, particularly, the linking of regulated and unregulated digital wallets when there is established common ownership and a desire to achieve rapid linking of those different accounts supported across disparate platforms for inter-dependent wallet operation, especially in the context of Web 3.0.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
